The purpose of this study is to evaluate the safety, dose, immunogenicity and early
clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in
combination with nivolumab and ipilimumab, in patients with metastatic non-small cell
lung cancer, microsatellite stable colorectal cancer, gastroesophageal adenocarcinoma,
and metastatic urothelial cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03639714.
Locations matching your search criteria
United States
New York
New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterStatus: Active
Name Not Available
Tumors harboring non-synonymous deoxyribonucleic acid (DNA) mutations can present
peptides containing these mutations as non-self antigens in the context of HLA on the
tumor cell surface. A fraction of mutated peptides result in neoantigens capable of
generating T-cell responses that exclusively target tumor cells. Sensitive detection of
these mutations allows for the identification of neoantigens unique to each patient's
tumor to be included in a personalized cancer vaccine that targets these neoantigens.
This vaccine regimen uses two vaccine vectors as a heterologous prime/boost approach
(GRT-C901 first followed by GRT-R902) to stimulate an immune response. This study will
explore the safety and early clinical activity of this patient-specific immunotherapy
intended to induce T-cell responses specific for neoantigens.
Lead OrganizationGritstone bio, Inc.
